Welcome to our dedicated page for DRUGS MADE IN AMER ACQUISITION SEC filings (Ticker: DMAAU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Drugs Made In America Acquisition Corp. (DMAAU) is a blank check company whose securities are registered in connection with its initial public offering on the Nasdaq Global Market. Although no specific SEC filings are listed here in this dataset, the company’s public statements reference a registration statement on Form S‑1 that was declared effective by the U.S. Securities and Exchange Commission in connection with its IPO, along with a post‑effective amendment.
As a SPAC and shell company in the financial services sector, DMAAU’s SEC filings are expected to describe its structure as a Cayman Islands exempted company, the terms of its units, ordinary shares, and rights, and the general framework for its planned business combination activities. These documents typically outline the company’s intention to pursue a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses.
The company has stated that it intends to focus its search for a target in the pharmaceutical industry, with an emphasis on businesses that may help mitigate risks in the U.S. medical supply chain by supporting strategic on‑shoring of advanced domestic manufacturing technologies for critical drugs. Over time, investors can expect that key SEC reports, such as annual and quarterly reports and any merger‑related filings, would provide more detail on its acquisition progress and any proposed business combination.
On Stock Titan’s SEC filings page, users can access DMAAU’s regulatory documents as they become available through EDGAR, along with AI‑generated summaries that explain the structure and implications of each filing. This includes registration statements and, if and when they are filed, ongoing reports and any transaction‑related disclosures that describe the company’s efforts to complete an initial business combination.
Drugs Made in America Acquisition Corp. entered into a non-binding letter of intent with Power Analytics Global Corp. on April 7, 2026 for a potential de-SPAC transaction that would take Power Analytics public. The LOI anticipates a Target valuation of approximately $1.0 billion, subject to adjustment based on due diligence, capital structure, net debt, working capital and market conditions, and will require negotiation and execution of a definitive business combination agreement.
Drugs Made In America Acquisition Corp. entered into a financing arrangement with BV Advisory Partners, LLC, starting with a $100,000 interim convertible note as the first tranche of a contemplated $500,000 funding commitment. The note matures in six months, bears no interest, and can convert, at the investor’s option after a business combination, into shares of the combined entity at a 35% discount to the market price at conversion.
The company plans to use the proceeds for accounting, audit, and other business combination-related expenses and has not yet agreed to a merger. Under the related investment agreement, a second tranche of $200,000 is expected within 21 days, with remaining amounts available on an as-needed basis. The investor is also being offered at least 40% of the economic benefit equivalent to sponsor-level economics and has introduced a potential business combination target focused on artificial intelligence, machine learning, quantum analytics, and cybersecurity solutions, though no letter of intent or definitive agreement has been signed.
Drugs Made In America Acquisition Corp. reported leadership changes following issues at an affiliated SPAC’s working capital account. The sponsor of Drugs Made In America Acquisition II Corp. withdrew an aggregate $1,100,000 from the affiliate’s working capital account, including $325,000 to repay a working capital note and $208,000 for other offering costs and expenses. The affiliate’s financial statements also showed a $566,269 overpayment to the sponsor, and the sponsor later withdrew no less than $200,000 more to pay expenses unrelated to the affiliate. After the affiliate’s board directed the sponsor to return the full overpayment amount and learned on February 12, 2026 that it could not be repaid, the boards of the affiliate and the company requested the resignation of Lynn Stockwell as Chief Executive Officer, Executive Chair, and director. The board received her resignation effective February 28, 2026 and removed her from all roles. On the same date, Roger Bendelac was appointed Chief Executive Officer of the company; his compensation will be determined later.
Karpus Management reported beneficial ownership of 2,744,109 common shares of Drugs Made In America Acquisition Corp., equal to 8.19% of the class. The shares are held directly in accounts managed by Karpus, which states it has sole voting and sole dispositive power over the shares. Karpus is a New York-formed registered investment adviser that notes it is controlled by City of London Investment Group plc but maintains informational barriers so that voting and investment decisions are made independently by Karpus. The filing indicates the position is held in the ordinary course of business and not for the purpose of changing control of the issuer.